Skip to main content
Log in

The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

To assess the practical prognostic value of c-erbB2, we performed a study on 942 invasive ductal carcinomas treated with primary surgery between 1980 and 1986 in our center. We evaluated its expression by immunohistochemistry in paraffin-embedded tissue using a polyclonal antipeptide antibody. Of 942 tumors, 229 (24%) showed a positive membrane staining. We observed a significant association between c-erbB2 and Scarff-Bloom-Richardson grading (p < 0.0001) and a negative correlation between c-erbB2 and both estrogen and progesterone receptors (p < 0.0001). In our analysis, with respect to overall survival (OS), relapse-free survival (RFS), and metastasis-free survival (MFS), c-erbB2 was statistically significant (p ≤ 0.0001) for the whole group and the node-positive subgroup. In multivariate analysis, c-erbB2 appeared to be an independant variable for RFS and MFS in the node-negative group. However, in our hands, c-erbB2 had a poor prognostic value in comparison with the classical prognostic variables such as histological grade, nodal status (N), hormonal receptor status (estrogen and progesterone receptors), and tumor size, and it did not supersede the classical parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987

    Google Scholar 

  2. Guerin M, Galillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB2 and EGF receptor genes in inflammatory and non inflammatory breast cancer: Prognostic significance. Int J Cancer 43: 201–208, 1989

    Google Scholar 

  3. May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarue JC: Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 62: 430–435, 1990

    Google Scholar 

  4. Wolber RA, Dupuis BA, Wick MR: Expression of c-erbB2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol 96: 243–247, 1991

    Google Scholar 

  5. Gullick WJ, Tuzi NL, Kumar S, Paterson H, Quirke P, Venter DJ: c-erbB2 and c-myc genes and their expression in normal tissues and in human breast cancer. Cancer Cells 7: 393–398, 1989

    Google Scholar 

  6. Venter DJ, Tuzi NL, Kumar S, Gullick WJ: Overexpression of the c-erbB2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification. Lancet ii: 69–71, 1987

    Google Scholar 

  7. Parkes HC, Lillycrop K, Howell A, Craig RK: c-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 61: 39–45, 1990

    Google Scholar 

  8. Tsutsumi Y, Naber SP, DeLellis RA, Wolfe HJ, Marks PJ, McKenzie SJ, Yin S: Neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. Hum Pathol 21: 750–758, 1990

    Google Scholar 

  9. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, de Bortoli M: c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47: 833–838, 1991

    Google Scholar 

  10. Soubeyran I, Coindre JM, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A: Immunohistochemical determination of PS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 34: 119–128, 1995

    Google Scholar 

  11. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359, 1957

    Google Scholar 

  12. Børresen AL, Ottestad L, Gaustad A, Andersen TI, Heikkilä R, Jahnsen T, Tveit KM, Nesland JM: Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 62: 585–590, 1990

    Google Scholar 

  13. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650–655, 1991

    Google Scholar 

  14. Press MF, Schwartz AM: Her-2/neu and breast cancer. In: Prognostic markers in breast cancer: laboratory analysis of breast biopsies. USCAP 83rd Annual Meeting San Francisco 1994 (Abstract)

  15. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA, Testori A: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44–49, 1991

    Google Scholar 

  16. Ro J, El-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G: c-erbB-2 amplification in nodenegative human breast cancer. Cancer Res 49: 6941–6944, 1989

    Google Scholar 

  17. Seshadri R, Matthews C, Dobrovic A, Horsfall DJ: The significance of oncogene amplification in primary breast cancer. Int J Cancer 43: 270–272, 1989

    Google Scholar 

  18. Toikkhanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10: 1044–1048, 1992

    Google Scholar 

  19. Van de Vijver MJ, Mooi WJ, Peterse JL, Nusse R: Amplification and over-expression of the neu oncogene in human breast carcinomas. Eur J Surg Oncol 14: 111–114, 1988

    Google Scholar 

  20. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2 (neu) or c-myc protooncogenes in breast carcinomas correlate with poor shortterm prognosis. Oncogene 1: 423–430, 1987

    Google Scholar 

  21. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447–450, 1991

    Google Scholar 

  22. Zhou D, Battifora H, Yokota J, Yamamoto T, Cline MJ: Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 47: 6123–6125, 1987

    Google Scholar 

  23. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238–1243, 1988

    Google Scholar 

  24. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438, 1991

    Google Scholar 

  25. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701–6707, 1990

    Google Scholar 

  26. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120–1128, 1989

    Google Scholar 

  27. Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CHW: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087–2090, 1989

    Google Scholar 

  28. Barnes DM: Breast cancer and a proto-oncogene. c-erB-2 is a reliable prognostic marker. Br Med J 299: 1061, 1989

    Google Scholar 

  29. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439–443, 1991

    Google Scholar 

  30. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296–3303, 1991

    Google Scholar 

  31. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M, Yamamoto H: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 65: 1794–1800, 1990

    Google Scholar 

  32. De Potter CR, Beghin C, Makar AP, Vandekerckhove D, Roels HJ: The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer 45: 55–58, 1990

    Google Scholar 

  33. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Sâve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golough R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ, for the International (Ludwig) Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049–1056, 1992

    Google Scholar 

  34. Heintz NH, Leslie KO, Rogers LA, Howard PL: Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114: 160–163, 1990

    Google Scholar 

  35. Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H, Rochefort H: Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene 6: 431–437, 1991

    Google Scholar 

  36. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444–446, 1991

    Google Scholar 

  37. Querzoli P, Marchetti E, Fabris G, Marzola A, Ferretti S, Iacobelli S, Hazan R, King CR, Nenci I: Immunohistochemical expression of c-erbB-2 in human breast cancer by monoclonal antibody: correlation with lymph node and ER status. Tumori 76: 461–464, 1990

    Google Scholar 

  38. Perren TJ: c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63: 328–332, 1991

    Google Scholar 

  39. Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49: 7147–7152, 1989

    Google Scholar 

  40. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J, Yoshida T, Sakamoto H, Terada M, Sugimura T: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49: 3104–3108, 1989

    Google Scholar 

  41. Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, Lennard TJW, Angus B, Horne CHW: Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163: 105–110, 1991

    Google Scholar 

  42. Richner J, Gerber HA, Locher GW, Goldhirsch A, Gelber RD, Gullick WJ, Berger MS, Groner B, Hynes NE: c-erbB-2 protein expression in node negative breast cancer. Ann Oncol 1: 263–268, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quénel, N., Wafflart, J., Bonichon, F. et al. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases. Breast Cancer Res Tr 35, 283–291 (1995). https://doi.org/10.1007/BF00665980

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00665980

Key words

Navigation